Angiotensin Peptides and SARS-CoV-2: Insights from Peptide–Receptor Interactions

Study Background and Research Question

The renin-angiotensin system (RAS) is a tightly regulated hormonal cascade central to cardiovascular and renal physiology. Angiotensin I—a decapeptide with the sequence Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu—serves as the immediate precursor of angiotensin II, a potent effector in blood pressure regulation and vascular homeostasis. The COVID-19 pandemic has drawn added attention to this pathway due to the critical role of angiotensin-converting enzyme 2 (ACE2) as the main entry receptor for SARS-CoV-2. Recent evidence suggests that additional host factors, including the receptor tyrosine kinase AXL and neuropilin-1 (NRP1), may also mediate viral entry, especially in tissues with low ACE2 expression.

Against this backdrop, the study by Oliveira et al. (2025) addresses a fundamental question: Do naturally occurring angiotensin peptides modulate the binding affinity of the SARS-CoV-2 spike protein to its cellular receptors—and if so, what are the implications for viral infectivity and pathogenesis?

Key Innovation from the Reference Study

The reference work provides the first systematic biochemical evidence that select angiotensin peptides directly enhance the binding of the SARS-CoV-2 spike protein to host cell receptors beyond ACE2, with a particular emphasis on the AXL receptor. While previous studies have focused primarily on ACE2, Oliveira et al. demonstrate that the landscape of viral entry can be substantially altered by the presence of specific peptide fragments derived from the RAS cascade. This highlights a novel interface between cardiovascular peptide biology and viral-host interactions, suggesting that the metabolic context of the host could influence viral infectivity via peptide–receptor dynamics.

Methods and Experimental Design Insights

The researchers employed a series of antibody-based binding assays to quantify the interaction between recombinant SARS-CoV-2 spike protein and three cellular receptors: ACE2, NRP1, and AXL. Experimental conditions included both the full-length Angiotensin I peptide and a range of biologically relevant cleavage products, such as angiotensin II, angiotensin III, angiotensin IV, and various truncated fragments. Importantly, the structural specificity of these peptides—particularly modifications to the N- or C-terminus and substitutions at key residues—was systematically interrogated to determine their effect on spike–receptor binding affinity.

Protocol Parameters

• Peptide concentrations: 100 μM for binding assays, as described in the reference study.
• Incubation time: 1 hour at room temperature, followed by standardized washing and detection steps.
• Peptide modifications: Both wild-type and site-modified versions (e.g., Tyr4 to Val substitution, Tyr4 phosphorylation) were tested for functional effects.
• Assay detection: ELISA-based readout quantifying spike–receptor interaction in the presence or absence of angiotensin peptides.

Core Findings and Why They Matter

Oliveira et al. found that angiotensin II (the octapeptide product of ACE cleavage) causes a two-fold increase in SARS-CoV-2 spike binding specifically to the AXL receptor, but not to ACE2 or NRP1. Intriguingly, the full-length Angiotensin I (1–10) peptide—Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu—did not enhance spike–AXL binding. However, shorter peptide fragments, particularly those generated by C-terminal or N-terminal deletions of angiotensin II, produced even greater enhancement. Notably, angiotensin IV (3–8) caused up to a 2.7-fold increase in spike–AXL binding and also elevated binding to ACE2 and NRP1. The enhancement effect was further modulated by substitutions at the Tyr4 position, demonstrating that specific sequence motifs within the peptide backbone are critical for this interaction.

These results suggest that the local peptide milieu—such as may occur during cardiovascular stress or pharmacologic intervention—could modulate host susceptibility to SARS-CoV-2 by altering the efficiency of viral spike engagement with alternative cellular receptors. This mechanism may partly explain tissue tropism and differential disease outcomes seen in COVID-19, especially in cardiovascularly compromised patients (reference study).

Comparison with Existing Internal Articles

Existing internal resources, such as the article "Angiotensin I (human, mouse, rat): Decoding Precursor Dynamics", have previously detailed the structural and functional role of Angiotensin I in renin-angiotensin system research, particularly with respect to cardiovascular disease mechanisms and antihypertensive drug screening. The current reference study extends this knowledge by linking peptide cleavage products to viral pathogenesis, thereby offering a cross-domain perspective.

Scenario-driven guidance in "Scenario-Driven Solutions with Angiotensin I (human, mouse, rat)" reinforces the importance of experimental reproducibility in RAS workflows, a principle that is directly relevant when adapting binding assays or peptide screening protocols for virology or host–pathogen studies. The reference study's use of peptide modifications and sequence truncations can inform future protocol optimization, as elaborated in "Angiotensin I: Applied Workflows for Renin-Angiotensin System Studies".

Limitations and Transferability

While the peptide–receptor binding assays provide mechanistic insight, the study is limited by its in vitro design, which may not fully capture the complexity of in vivo peptide metabolism, tissue-specific expression, or dynamic regulation of receptors like AXL and NRP1. Furthermore, the concentrations of peptides used in binding assays may not reflect physiological or pathophysiological levels encountered during cardiovascular disease or pharmacologic intervention. The translational relevance thus warrants careful validation in animal models and clinical samples.

Why this cross-domain matters, maturity, and limitations

Bridging cardiovascular peptide signaling with viral pathogenesis is of high conceptual value. The reference paper shows that metabolic context—specifically, the repertoire of circulating angiotensin fragments—can influence viral entry pathways, potentially affecting infection severity or therapeutic responsiveness in patients with underlying RAS dysregulation. However, clinical implications remain speculative until further validated in vivo and in patient studies. The maturity of this cross-domain insight lies primarily at the mechanistic and preclinical stage.

Research Support Resources

For researchers seeking to replicate or extend these findings, high-purity Angiotensin I (human, mouse, rat) is available as SKU A1006 from APExBIO. This decapeptide provides a reliable starting point for generating downstream angiotensin fragments or for dissecting the effects of sequence modifications in binding assays. Its utility in cardiovascular, neuroendocrine, and host–virus interaction studies is further supported by optimized protocols detailed in internal resources. When planning new assays or modeling peptide–receptor interactions in animal systems, this reagent offers standardized quality and batch traceability for robust experimental outcomes.